{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:44:27Z","timestamp":1780544667234,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T00:00:00Z","timestamp":1641686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T00:00:00Z","timestamp":1641686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41433-021-01887-2","type":"journal-article","created":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T00:02:43Z","timestamp":1641686563000},"page":"54-61","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Vitreoretinal lymphoma: Central nervous system lymphoma risk with unilateral or bilateral ocular tumour. A multicentre collaboration"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4284","authenticated-orcid":false,"given":"Lauren A.","family":"Dalvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose S.","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-3632","authenticated-orcid":false,"given":"Carol L.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-7261","authenticated-orcid":false,"given":"Alessandro","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Miserocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3688-8676","authenticated-orcid":false,"given":"Shahar","family":"Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Pe\u2019er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,9]]},"reference":[{"key":"1887_CR1","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","volume":"16","author":"CC Chan","year":"2011","unstructured":"Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011;16:1589\u201399.","journal-title":"Oncologist"},{"key":"1887_CR2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/09273948.2020.1787460","volume":"29","author":"C Giuffr\u00e8","year":"2020","unstructured":"Giuffr\u00e8 C, Cicinelli MV, Marchese A, Modorati GM, Brambati M, Ferreri AJM, et al. Clinical experience in a large cohort of patients with vitreoretinal lymphoma in a single center. Ocul Immunol Inflamm. 2020;29:472\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"1887_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/bjo.2007.127928","volume":"92","author":"S Frenkel","year":"2008","unstructured":"Frenkel S, Hendler K, Siegal T, Shalom E, Pe\u2019er J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92:383\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1887_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-018-0120-4","volume":"4","author":"JS Pulido","year":"2018","unstructured":"Pulido JS, Johnston PB, Nowakowski GS, Castellino A, Raja H. The diagnosis and treatment of primary vitreoretinal lymphoma: a review. Int J Retin Vitreous. 2018;4:18.","journal-title":"Int J Retin Vitreous"},{"key":"1887_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/APO.0000000000000274","volume":"9","author":"LA Dalvin","year":"2020","unstructured":"Dalvin LA, Lim LS, Ancona-Lezama D, Mazloumi M, Chang M, Porcu P, et al. Clinical features predictive of survival in patients with vitreoretinal lymphoma: analysis of 70 patients at a single ocular oncology center. Asia Pac J Ophthalmol. 2020;9:110\u20136.","journal-title":"Asia Pac J Ophthalmol"},{"key":"1887_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0002-9394(68)92065-5","volume":"66","author":"MH Vogel","year":"1968","unstructured":"Vogel MH, Font RL, Zimmerman LE, Levine RA. Reticulum cell sarcoma of the retina and uvea. Report of six cases and review of the literature. Am J Ophthalmol. 1968;66:205\u201315.","journal-title":"Am J Ophthalmol"},{"key":"1887_CR7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/0002-9394(81)90236-1","volume":"91","author":"DH Char","year":"1981","unstructured":"Char DH, Margolis L, Newman AB. Ocular reticulum cell sarcoma. Am J Ophthalmol. 1981;91:480\u20133.","journal-title":"Am J Ophthalmol"},{"key":"1887_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/ICU.0000000000000255","volume":"27","author":"D Reichstein","year":"2016","unstructured":"Reichstein D. Primary vitreoretinal lymphoma: an update on pathogenesis, diagnosis and treatment. Curr Opin Ophthalmol. 2016;27:177\u201384.","journal-title":"Curr Opin Ophthalmol"},{"key":"1887_CR9","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jamaophthalmol.2013.334","volume":"131","author":"DR Salomao","year":"2013","unstructured":"Salomao DR, Pulido JS, Johnston PB, Canal-Fontcuberta I, Feldman AL. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma. JAMA Ophthalmol. 2013;131:1151\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"1887_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3109\/09273940903370755","volume":"17","author":"J Pe\u2019er","year":"2009","unstructured":"Pe\u2019er J, Hochberg FH, Foster CS. Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm. 2009;17:299\u2013306.","journal-title":"Ocul Immunol Inflamm"},{"key":"1887_CR11","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.survophthal.2021.03.004","volume":"66","author":"V Raval","year":"2021","unstructured":"Raval V, Binkley E, Aronow ME, Valenzuela J, Peereboom DM, Singh AD. Primary central nervous system lymphoma - ocular variant (PCNSL-O): an interdisciplinary review on management. Surv Ophthalmol. 2021;66:1009\u201320.","journal-title":"Surv Ophthalmol"},{"key":"1887_CR12","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s10792-021-01805-1","volume":"41","author":"P Rishi","year":"2021","unstructured":"Rishi P, Manchegowda PT, Gondhale HP, Rishi E, Das K, Krishnakumar S, et al. Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma: initial experience from India. Int Ophthalmol. 2021;41:2495\u20132504.","journal-title":"Int Ophthalmol"},{"key":"1887_CR13","doi-asserted-by":"publisher","first-page":"e65627","DOI":"10.1371\/journal.pone.0065627","volume":"8","author":"H Raja","year":"2013","unstructured":"Raja H, Snyder MR, Johnston PB, O\u2019Neill BP, Caraballo JN, Balsanek JG, et al. Effect of intravitreal methotrexate and rituximab on interleukin-10 levels in aqueous humor of treated eyes with vitreoretinal lymphoma. PLoS ONE. 2013;8:e65627.","journal-title":"PLoS ONE"},{"key":"1887_CR14","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/IAE.0000000000002851","volume":"40","author":"AW Stacey","year":"2020","unstructured":"Stacey AW, Pulido JS. The concept of minimal residual disease in the treatment and staging of vitreoretinal lymphoma. Retina. 2020;40:1213\u20134.","journal-title":"Retina"},{"key":"1887_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/bjh.17451","volume":"194","author":"Z Habot-Wilner","year":"2021","unstructured":"Habot-Wilner Z, Frenkel S, Pe\u2019er J. Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience. Br J Haematol. 2021;194:92\u2013100.","journal-title":"Br J Haematol"},{"key":"1887_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ajh.25350","volume":"94","author":"A Castellino","year":"2018","unstructured":"Castellino A, Pulido JS, Johnston PB, Ristow KM, Nora Bennani N, Inwards DJ, et al. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: a single center experience 1990\u20132018. Am J Hematol. 2018;94:291\u20138.","journal-title":"Am J Hematol"},{"key":"1887_CR17","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/annonc\/mdm340","volume":"18","author":"SA Grimm","year":"2007","unstructured":"Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group report. Ann Oncol. 2007;18:1851\u20135.","journal-title":"Ann Oncol"},{"key":"1887_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jamaophthalmol.2014.4755","volume":"133","author":"A Riemens","year":"2015","unstructured":"Riemens A, Bromberg J, Touitou V, Sobolewska B, Missotten T, Baarsma S, et al. Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol. 2015;133:191\u20137.","journal-title":"JAMA Ophthalmol"},{"key":"1887_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00417-014-2584-8","volume":"252","author":"N Hashida","year":"2014","unstructured":"Hashida N, Nakai K, Saitoh N, Nishida K. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma. Graefe\u2019s Arch Clin Exp Ophthalmol. 2014;252:687\u201393.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"1887_CR20","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaophthalmol.2017.3286","volume":"135","author":"AH Ahmed","year":"2017","unstructured":"Ahmed AH, Foster CS, Shields CL. Association of disease location and treatment with survival in diffuse large B-cell lymphoma of the eye and ocular adnexal region. JAMA Ophthalmol. 2017;135:1062\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"1887_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1076\/ocii.8.4.243.6463","volume":"8","author":"N Cassoux","year":"2000","unstructured":"Cassoux N, Merle-Beral H, Leblond V, Bodaghi B, Milea D, Gerber S, et al. Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm. 2000;8:243\u201350.","journal-title":"Ocul Immunol Inflamm"},{"key":"1887_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00417-005-0138-9","volume":"244","author":"K Jahnke","year":"2006","unstructured":"Jahnke K, Korfel A, Komm J, Bechrakis NE, Stein H, Thiel E, et al. Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial. Graefe\u2019s Arch Clin Exp Ophthalmol. 2006;244:663\u20139.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"1887_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/09273948.2017.1421669","volume":"26","author":"BJ Cho","year":"2018","unstructured":"Cho BJ, Kim DY, Park UC, Lee JY, Yoon YH, Yu HG. Clinical features and treatment outcomes of vitreoretinal lymphoma according to its association with CNS lymphoma. Ocul Immunol Inflamm. 2018;26:365\u201371.","journal-title":"Ocul Immunol Inflamm"},{"key":"1887_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/COC.0000000000000028","volume":"39","author":"MM Kim","year":"2016","unstructured":"Kim MM, Dabaja BS, Medeiros J, Kim S, Allen P, Chevez-Barrios P, et al. Survival outcomes of primary intraocular lymphoma: a single-institution experience. Am J Clin Oncol. 2016;39:109\u201313.","journal-title":"Am J Clin Oncol"},{"key":"1887_CR25","first-page":"00509","volume":"S0002-9394","author":"MC Santos","year":"2021","unstructured":"Santos MC, Jiang A, Li AS, Rao PK, Wilson B, Harocopos GJ. Vitreoretinal lymphoma: optimizing diagnostic yield and accuracy. Am J Ophthalmol. 2021;S0002-9394:00509\u20132.","journal-title":"Am J Ophthalmol"},{"key":"1887_CR26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/09273948.2021.1878233","volume":"29","author":"D Carbonell","year":"2021","unstructured":"Carbonell D, Mahajan S, Chee SP, Sobolewska B, Agrawal R, B\u00fclow T, et al. Consensus recommendations for the diagnosis of vitreoretinal lymphoma. Ocul Immunol Inflamm. 2021;29:507\u201320.","journal-title":"Ocul Immunol Inflamm"},{"key":"1887_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/bjophthalmol-2013-304043","volume":"98","author":"KL Larkin","year":"2014","unstructured":"Larkin KL, Saboo US, Comer GM, Forooghian F, Mackensen F, Merrill P, et al. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. Br J Ophthalmol. 2014;98:99\u2013103.","journal-title":"Br J Ophthalmol"},{"key":"1887_CR28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamaophthalmol.2017.1810","volume":"135","author":"CL Shields","year":"2017","unstructured":"Shields CL, Sioufi K, Mashayekhi A, Shields JA. Intravitreal melphalan for treatment of primary vitreoretinal lymphoma: a new indication for an old drug. JAMA Ophthalmol. 2017;135:815\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"1887_CR29","first-page":"93","volume":"15","author":"CC Chan","year":"2013","unstructured":"Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med. 2013;15:93\u2013100.","journal-title":"Discov Med"},{"key":"1887_CR30","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/ajh.26199","volume":"96","author":"M Lam","year":"2021","unstructured":"Lam M, Touitou V, Choquet S, Cassoux N, Ghesqui\u00e8res H, Kodjikian L, et al. Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study. Am J Hematol. 2021;96:823\u201333.","journal-title":"Am J Hematol"},{"key":"1887_CR31","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7:1018\u20131029.","journal-title":"Cancer Discov"},{"key":"1887_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"C Soussain","year":"2019","unstructured":"Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121\u201330.","journal-title":"Eur J Cancer"},{"key":"1887_CR33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/ejh.13667","volume":"107","author":"L Renaud","year":"2021","unstructured":"Renaud L, Bossard JB, Carpentier B, Terriou L, Cambier N, Chanteau G, et al. Treatment with temozolomide and ibrutinib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Eur J Haematol. 2021;107:370\u20133.","journal-title":"Eur J Haematol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01887-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01887-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01887-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T15:11:31Z","timestamp":1673622691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01887-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1887"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01887-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,9]]},"assertion":[{"value":"13 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}